FAQ
Drugs

What information on impurities in the drug substance should be included in CTD Section 3.2.S.3.2 when submitting a DMF/API application?

刊登日期:2020-07-22  |  點閱次數 : 769 次 

The following information should be included:

  1. 1. The origins, control strategies, analysis data, analytical methods, historical analysis data of related substance (process-related impurities and degradation products) should be provided. In addition, information on residual solvents, reagents, elemental impurities, and potentially genotoxic/mutagenic impurities that are observed and/or generated in the manufacturing process and during storage period should be provided.
  2. 2. The structural elucidation data of specified impurities listed in drug substance specification should be provided.

(中文版)


上一筆 What information should be provided when there are multiple sources for a startin
下一筆 For starting materials that are not commercially available, what information shou